Biological Dynamics of Forest Fragments Project Area of Relevant Ecological Interest

Biological Dynamics Announces Early Access Program to Its ExoVerita™ Pro Platform

Retrieved on: 
Wednesday, November 8, 2023
Oncology, Health, Health Technology, Genetics, Research, Science, Biotechnology, Plasma, Extracellular vesicle, AMP, RNA, Special access program, Exosome, Conference, ACE, Cell, DNA, Glossary of biology, Biological Dynamics of Forest Fragments Project Area of Relevant Ecological Interest, Disease, Centrifuge, Annual general meeting, Serum, Cancer, Diagnosis, Prognosis, Fluid mechanics, Pharmaceutical industry

Biological Dynamics, Inc. , the leader in exosome-isolation technology, today announced the first opportunity for external users to access the company’s ExoVerita Pro, a cost-efficient, automated exosomal enrichment platform that delivers samples with best-in-class yields, purity, and reproducibility.

Key Points: 
  • Biological Dynamics, Inc. , the leader in exosome-isolation technology, today announced the first opportunity for external users to access the company’s ExoVerita Pro, a cost-efficient, automated exosomal enrichment platform that delivers samples with best-in-class yields, purity, and reproducibility.
  • “Technology is revolutionizing our understanding and management of some of our most challenging diseases,” said Paul R. Billings, M.D., Ph.D., CEO and Director of Biological Dynamics.
  • Biological Dynamics’ ExoVerita technology platform offers an automated workflow for successfully detecting and recovering exosomes that have benefits over other methods, such as ultracentrifugation and column purification.
  • Biological Dynamics will showcase its Early Access Program and products at the Association for Molecular Pathology (AMP) Annual Meeting in Salt Lake City, Utah, Nov. 14-18, and will debut ExoVerita Pro at the SelectBio Conference in Laguna Hills, Calif., Nov. 28-30.

Biological Dynamics to Share Data at 2023 Early Detection of Cancer Conference in London, Highlighting Value of Exosome-based Liquid Biopsy Assay in Detecting Pancreatic Cysts

Retrieved on: 
Thursday, October 5, 2023
Oncology, Health, Health Technology, Other Health, General Health, Biotechnology, Pancreas, Biology, Physician, Exosome, Pancreatic cancer, Pancreatic cyst, Intraductal papillary mucinous neoplasm, Master of Science, Risk, IPMN, Survival, Cancer, Medical director, Patient, Q&A, Biological Dynamics of Forest Fragments Project Area of Relevant Ecological Interest, Conference, Expression, Pharmaceutical industry, MD

Biological Dynamics, Inc. , a leader in exosome enrichment technology for early disease detection, will present a “lightning talk” as part of the “Understanding Pre-cancers to Enable Early Detection” track at the Early Detection of Cancer Conference , Oct. 10-12, 2023, in London.

Key Points: 
  • Biological Dynamics, Inc. , a leader in exosome enrichment technology for early disease detection, will present a “lightning talk” as part of the “Understanding Pre-cancers to Enable Early Detection” track at the Early Detection of Cancer Conference , Oct. 10-12, 2023, in London.
  • The ExoVita Pancreas assay leverages Biological Dynamics’ proprietary Verita™ technology, a novel platform that enriches exosomes and facilitates proteomic analysis.
  • This powerful method provides high-sensitivity detection of pancreatic cancer in its early stages, resulting in improved treatment options for this deadly disease.
  • Biological Dynamics is partnering with the PRECEDE consortium to validate the ExoVita Pancreas assay for both IPMNs and other patients at high risk for developing cancer.

Biological Dynamics and The Pancreatic Cancer Early Detection Consortium (PRECEDE) Collaborate to Improve Surveillance of Early Pancreatic Cancer

Retrieved on: 
Wednesday, September 6, 2023
Research, Medical Devices, Genetics, Clinical Trials, Health Technology, Biotechnology, Radiology, Health, Science, Oncology, Survival rate, PDAC, Pancreatic cancer, Pancreatitis, Biological Dynamics of Forest Fragments Project Area of Relevant Ecological Interest, University, Consortium, Survival, Exosome, Liquid biopsy, Cancer, Pancreas, Prognosis, Multimedia, University of Pittsburgh School of Medicine, Biomarker, Biology, Patient, Risk, Wilfrid Sellars, III, Diagnosis, Pharmaceutical industry, Medical imaging, Verita, Medicine

Biological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, and the Pancreatic Cancer Early Detection (PRECEDE) Consortium, an international, multi-institutional group of experts focused on increasing survival rates for pancreatic cancer patients, have signed a multi-year agreement to partner on patient surveillance for early-stage pancreatic cancer using Biological Dynamics’ ExoVita Pancreas Assay, powered by the Verita platform.

Key Points: 
  • Biological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, and the Pancreatic Cancer Early Detection (PRECEDE) Consortium, an international, multi-institutional group of experts focused on increasing survival rates for pancreatic cancer patients, have signed a multi-year agreement to partner on patient surveillance for early-stage pancreatic cancer using Biological Dynamics’ ExoVita Pancreas Assay, powered by the Verita platform.
  • View the full release here: https://www.businesswire.com/news/home/20230906960007/en/
    Biological Dynamics is PRECEDE’s first liquid biopsy partner, supporting the goal to detect cancer earlier and improve survival rates.
  • The collaboration accelerates enrollment of at least 5,000 patients into Biological Dynamics’ ExoLuminate Study ( NCT05625529 ), a multi-site clinical study designed for individuals with an elevated risk of pancreatic cancer to detect early pancreatic ductal adenocarcinoma (PDAC).
  • ExoVita Pancreas is powered by Biological Dynamics’ Verita platform, which targets and isolates blood-based exosomal protein biomarkers, enabling high-sensitivity detection of cancer in its early stages.

New Study Demonstrates Efficient Exosome Isolation from Biological Fluids Using Proprietary Technology from Biological Dynamics

Retrieved on: 
Wednesday, July 26, 2023
Oncology, Medical Supplies, Health, Health Technology, Clinical Trials, Research, Science, Extracellular vesicle, Nanoparticle, Collection, Biological Dynamics of Forest Fragments Project Area of Relevant Ecological Interest, Doctor of Philosophy, Serum, Oregon Health & Science University, Exosome, Cancer, Cell, Biomarker, Electrophoresis, Biology, Plasma, Glossary of biology, MD, OHSU, Blood, Department of Computer Science, University of Manchester, ACE, Dielectrophoresis, Particle collection in wet scrubbers, Pharmaceutical industry, Medical imaging

Biological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, announced a newly published study in the journal Electrophoresis titled, “ Enhancement of Dielectrophoresis-Based Particle Collection from High Conducting Fluids Due to Partial Electrode Insulation.

Key Points: 
  • Biological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, announced a newly published study in the journal Electrophoresis titled, “ Enhancement of Dielectrophoresis-Based Particle Collection from High Conducting Fluids Due to Partial Electrode Insulation.
  • ” The collaborative research with Oregon Health & Science University (OHSU) sheds light on the phenomenon occurring on Biological Dynamics’ ExoVerita platform that allows for the capture of biomarkers carried by nanoscale particles.
  • Biological Dynamics’ proprietary lab-on-a-chip platform leverages AC Electrokinetics (ACE) technology for the isolation of exosomes from undiluted biofluids, such as whole blood, plasma, and serum.
  • "I look forward to seeing how the advancements we make with the technique improve the capability of diagnostic tools to detect and analyze diseases."

Biological Dynamics Case Report Published in Frontiers in Oncology Demonstrates Advancement in the Detection of Early-Stage Pancreatic Lesions

Retrieved on: 
Friday, May 26, 2023
Oncology, Health, Health Technology, Clinical Trials, Research, Science, Biotechnology, PDAC, Pancreatic cancer, Biological Dynamics of Forest Fragments Project Area of Relevant Ecological Interest, Survival, Exosome, Cancer, Prognosis, Biomarker, IPMN, Biology, II, Conditional sentence, Patient, Physician, Acute pancreatitis, Diagnosis, United, Pancreas, Malignancy, United States $1 Coin Act of 1997, Medical imaging, Pharmaceutical industry, Frontiers

The case report suggests that the high sensitivity and specificity of the ExoVita Pancreas for early-stage PDAC detection have the potential to improve patient survival outcomes significantly.

Key Points: 
  • The case report suggests that the high sensitivity and specificity of the ExoVita Pancreas for early-stage PDAC detection have the potential to improve patient survival outcomes significantly.
  • Unfortunately, pancreatic cancer usually shows little or no symptoms until it has advanced and spread.
  • “In this case, our assay, which was initially trained on stage I and II pancreatic cancer patient samples, successfully detected exosomes from an early-stage lesion.
  • The patient underwent ten months of invasive procedures and testing that failed to detect radiographic evidence of pancreatic lesions or identify disease concerns.

Biological Dynamics launches ExoVita™ Pancreas and enrolls patients in ExoLuminate clinical trial

Retrieved on: 
Wednesday, February 8, 2023
Oncology, Health, Other Science, Clinical Trials, Research, Science, Biotechnology, Master of Science, Community-based clinical trial, Pancreas, CLIA, Biological Dynamics of Forest Fragments Project Area of Relevant Ecological Interest, Pancreatitis, LDT, Patient, RUO, Medical Affairs Bureau, Exosome, Biology, PDAC, CAP, Pharmaceutical industry, Medical imaging, MD

With this validation, samples from the ExoLuminate registry trial ( NCT05625529 ), a trial which has already begun actively enrolling patients with high-risk for PDAC to investigate the test’s clinical utility, will be tested by the company.

Key Points: 
  • With this validation, samples from the ExoLuminate registry trial ( NCT05625529 ), a trial which has already begun actively enrolling patients with high-risk for PDAC to investigate the test’s clinical utility, will be tested by the company.
  • “Our published, high sensitivity ExoVita Pancreas assay for early-stage pancreatic cancer is being further validated with prospective clinical samples from our ExoLuminate registry trial.
  • ExoVita Pancreas is a ‘Research Use Only’ (RUO) test produced from Biological Dynamics’ CAP/CLIA certified lab.
  • Any and all clinical decision-making remains with each study patient participant and their physician providers.

Biological Dynamics, Perlmutter Cancer Center at NYU Langone Health collaborate on pancreatic cancer research

Retrieved on: 
Tuesday, January 31, 2023
Oncology, Health, Other Science, Research, Science, Biotechnology, Biomarker, Cancer, Blood, Partnership, Publication, Diagnosis, Biological Dynamics of Forest Fragments Project Area of Relevant Ecological Interest, LDT, Patient, Exosome, NYU, PDAC, NYU Langone Health, Pancreatic cancer, ACE, Doctor of Philosophy, MD, Pharmaceutical industry, Medical imaging

Biological Dynamics , a company commercializing its exosome-isolation ExoVerita™ platform, announced a collaboration with the Perlmutter Cancer Center at NYU Langone Health to validate its application for the early detection of pancreatic ductal adenocarcinoma (PDAC).

Key Points: 
  • Biological Dynamics , a company commercializing its exosome-isolation ExoVerita™ platform, announced a collaboration with the Perlmutter Cancer Center at NYU Langone Health to validate its application for the early detection of pancreatic ductal adenocarcinoma (PDAC).
  • The ExoVerita™ platform is being investigated at NYU Langone Health, among other premier institutions, with a goal of advancing treatment options for high-risk PDAC patients.
  • Exploring new technologies that can detect cancers sooner in high-risk patients is critical to improving patient outcomes and the quality-of-life years following diagnosis,” says principal investigator, Diane Simeone, MD, surgical oncologist and director, pancreatic cancer center at NYU Langone’s Perlmutter Cancer Center.
  • Our goal is to improve outcomes for high-risk patients predisposed to pancreatic cancer,” concluded Dr. Balcer.

Biological Dynamics to deliver showcase presentation at Precision Medicine World Conference

Retrieved on: 
Tuesday, January 24, 2023
Oncology, Health, Biometrics, Genetics, Clinical Trials, Biotechnology, MBA, Master of Science, Biomarker, Cancer, Blood, Biological Dynamics of Forest Fragments Project Area of Relevant Ecological Interest, Patient, Georgetown University, Seminal vesicles, Exosome, HPB, Liquid biopsy, Conference, PDAC, Medicine, UCSD, Medical imaging, MD

Biological Dynamics , a company developing and commercializing its ExoVeritaTM platform for early disease diagnostics, announced today that Harmeet Dhani, MD, MSc, Medical Director will present at the Precision Medicine World Conference (PMWC) in Santa Clara, Calif.

Key Points: 
  • Biological Dynamics , a company developing and commercializing its ExoVeritaTM platform for early disease diagnostics, announced today that Harmeet Dhani, MD, MSc, Medical Director will present at the Precision Medicine World Conference (PMWC) in Santa Clara, Calif.
    Dr. Dhani’s PMWC showcase presentation on January 26th is part of the Clinical Utility of Liquid Biopsies track.
  • Biological Dynamics’ ExoVerita platform targets extracellular vesicles in blood, isolating exosomes to detect biomarkers of early-stage cancers.
  • “Leveraging the innovations of our ExoVerita platform, we are developing solutions for patients, their families and the medical community.
  • He also holds a Master’s in Clinical Research from UCSD and anticipates completing his MBA from Georgetown University in 2025.

Biological Dynamics Appoints Industry Veteran Peter Wulff as Chief Financial Officer

Retrieved on: 
Tuesday, January 17, 2023
EVS, Financial management, Seminal vesicles, MD, Biological Dynamics of Forest Fragments Project Area of Relevant Ecological Interest, Intellectual property, Growth, Cancer, Exosome, SAN, Doctor of Philosophy, Investment, Pharmaceutical industry

SAN DIEGO, Jan. 17, 2023 /PRNewswire/ -- Biological Dynamics , Inc., a company developing and commercializing its proprietary ExoVerita™ platform for early disease detection and other applications, today announced Peter C. Wulff as Chief Financial Officer effective January 1, 2023.

Key Points: 
  • SAN DIEGO, Jan. 17, 2023 /PRNewswire/ -- Biological Dynamics , Inc., a company developing and commercializing its proprietary ExoVerita™ platform for early disease detection and other applications, today announced Peter C. Wulff as Chief Financial Officer effective January 1, 2023.
  • Mr. Wulff has over 35 years of financial management experience in both public and privately held companies in emerging growth life sciences.
  • He most recently served as Chief Financial Officer at JenaValve Technology, where he played an instrumental role in the corporate relocation from Germany and subsequent growth of its US operations.
  • "I am honored to join Biological Dynamics, and look forward to enhancing efforts to drive adoption of our novel and proprietary technology for early disease detection," said Peter Wulff.

Biological Dynamics, an early detection disease management company, expands leadership

Retrieved on: 
Thursday, November 10, 2022
SAN, Biological Dynamics of Forest Fragments Project Area of Relevant Ecological Interest, Alacrity, Health care, AACC, PDAC, MaxLinear, Food, Research, Laboratory developed test, UC, UC San Diego Health, Regulation of tobacco by the U.S. Food and Drug Administration, Ernst & Young, Nall, Moores Cancer Center, GE Healthcare, Cancer, Biomarker, Patient, Growth, CEO, Blake Enever, Industry, Acquisition, Diagnosis, LDT, Pharmaceutical industry, Management, LabCorp

SAN DIEGO, Nov. 10, 2022 /PRNewswire/ -- Biological Dynamics, an exosome isolation technology and early disease detection company, today announced new executive appointments to fuel its growth.

Key Points: 
  • SAN DIEGO, Nov. 10, 2022 /PRNewswire/ -- Biological Dynamics, an exosome isolation technology and early disease detection company, today announced new executive appointments to fuel its growth.
  • Nall leads the commercialization strategy of the Laboratory Developed Tests (LDTs) to detect the early stages of cancer.
  • As the company prepares for growth, Michael Russell has replaced Biological Dynamics' cofounder, Dr. Raj Krishnan, as a director.
  • Our team is driven every day to bring innovative solutions to patients, their families and the biomedical community with a focus on early diagnostic disease detection applications, particularly in cancer.